-
1
-
-
33845404984
-
Fistulizing Crohn's disease
-
Sartor RB, Sandborn WJ, eds, 6th ed. New York: W.B. Saunders;
-
Judge TA, Lichenstein GR. Fistulizing Crohn's disease. In: Sartor RB, Sandborn WJ, eds. Kirsner's Inflammatory Bowel Diseases. 6th ed. New York: W.B. Saunders; 2004:700-716.
-
(2004)
Kirsner's Inflammatory Bowel Diseases
, pp. 700-716
-
-
Judge, T.A.1
Lichenstein, G.R.2
-
2
-
-
0030068415
-
Perianal Crohn's disease - is it all bad news?
-
McKee RF, Keenan RA. Perianal Crohn's disease - is it all bad news? Dis Colon Rectum. 1996;39:136-142.
-
(1996)
Dis Colon Rectum
, vol.39
, pp. 136-142
-
-
McKee, R.F.1
Keenan, R.A.2
-
3
-
-
34548379894
-
Perianal Crohn's disease: Classification and clinical evaluation
-
Vermeire S, Van Assche G, Rutgeerts P. Perianal Crohn's disease: classification and clinical evaluation. Dig Liver Dis. 2007;39:959-962.
-
(2007)
Dig Liver Dis
, vol.39
, pp. 959-962
-
-
Vermeire, S.1
Van Assche, G.2
Rutgeerts, P.3
-
4
-
-
0031779091
-
Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients
-
Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998;114:1151-1160.
-
(1998)
Gastroenterology
, vol.114
, pp. 1151-1160
-
-
Lapidus, A.1
Bernell, O.2
Hellers, G.3
-
6
-
-
0028010074
-
Immune mechanisms in chronic inflammatory bowel disease
-
Braegger CP, MacDonald TT. Immune mechanisms in chronic inflammatory bowel disease. Ann Allergy. 1994;72:135-141.
-
(1994)
Ann Allergy
, vol.72
, pp. 135-141
-
-
Braegger, C.P.1
MacDonald, T.T.2
-
7
-
-
16244379546
-
Regulatory T cells and intestinal homeostasis
-
Coombes JL, Robinson NJ, Maloy KJ, et al. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-94.
-
(2005)
Immunol Rev
, vol.204
, pp. 184-194
-
-
Coombes, J.L.1
Robinson, N.J.2
Maloy, K.J.3
-
8
-
-
32044451548
-
Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial
-
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
-
9
-
-
8344284998
-
Anti-IL-12 Crohn's Disease Study Group. Antiinterleukin-12 antibody for active Crohn's disease
-
Mannon PJ, Fuss IJ, Mayer L, et al. Anti-IL-12 Crohn's Disease Study Group. Antiinterleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
-
(2004)
N Engl J Med
, vol.351
, pp. 2069-2079
-
-
Mannon, P.J.1
Fuss, I.J.2
Mayer, L.3
-
10
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
-
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
van Deventer, S.J.3
-
11
-
-
19444380965
-
Local injection of infliximab for the treatment of perianal Crohn's disease
-
Poggioli G, Laureti S, Pierangeli F, et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005; 48:768-774.
-
(2005)
Dis Colon Rectum
, vol.48
, pp. 768-774
-
-
Poggioli, G.1
Laureti, S.2
Pierangeli, F.3
-
12
-
-
0036144887
-
Endosonographic evidence of persistence of Crohn's disease associated fistulas after infliximab treatment, irrespective of clinical response
-
Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, et al. Endosonographic evidence of persistence of Crohn's disease associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39-45.
-
(2002)
Dis Colon Rectum
, vol.45
, pp. 39-45
-
-
Van Bodegraven, A.A.1
Sloots, C.E.2
Felt-Bersma, R.J.3
-
13
-
-
0037282938
-
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
-
Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 332-339
-
-
Van Assche, G.1
Vanbeckevoort, D.2
Bielen, D.3
-
14
-
-
34250222082
-
Cytokine network in chronic perianal Crohn's disease and indeterminate colitis after colectomy
-
Ruffolo C, Scarpa M, Faggian D, et al. Cytokine network in chronic perianal Crohn's disease and indeterminate colitis after colectomy. J Gastrointest Surg. 2007;11:16-21.
-
(2007)
J Gastrointest Surg
, vol.11
, pp. 16-21
-
-
Ruffolo, C.1
Scarpa, M.2
Faggian, D.3
-
15
-
-
0028873006
-
Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group
-
Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27-32.
-
(1995)
J Clin Gastroenterol
, vol.20
, pp. 27-32
-
-
Irvine, E.J.1
-
16
-
-
0017227303
-
Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study
-
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
-
(1976)
Gastroenterology
, vol.70
, pp. 439-444
-
-
Best, W.R.1
Becktel, J.M.2
Singleton, J.W.3
-
17
-
-
0018292706
-
National Cooperative Crohn's Disease Study: Study design and conduct of the study
-
Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology. 1979;77:829-842.
-
(1979)
Gastroenterology
, vol.77
, pp. 829-842
-
-
Winship, D.H.1
Summers, R.W.2
Singleton, J.W.3
-
18
-
-
4644313604
-
C-reactive protein as a marker for inflammatory bowel disease
-
Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10:661-665.
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 661-665
-
-
Vermeire, S.1
Van Assche, G.2
Rutgeerts, P.3
-
20
-
-
0022621499
-
Indium 111-granulocyte scanning in the assessment of disease activity in inflammatory bowel disease: A comparison with colonscopy, histology, and fecal indium 111-granulocyte excretion
-
Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111-granulocyte scanning in the assessment of disease activity in inflammatory bowel disease: a comparison with colonscopy, histology, and fecal indium 111-granulocyte excretion. Gastoenterology. 1986;90:1121-1128.
-
(1986)
Gastoenterology
, vol.90
, pp. 1121-1128
-
-
Saverymuttu, S.H.1
Camilleri, M.2
Rees, H.3
-
21
-
-
0017184389
-
A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding
-
Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:348-354.
-
(1976)
Anal Biochem
, vol.72
, pp. 348-354
-
-
Bradford, M.M.1
-
22
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
-
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
van Deventer, S.J.3
-
23
-
-
34347402306
-
Adalimumab induction therapy for crohn disease previously treated with infliximab. A randomized trial
-
Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med. 2007;146:829-838
-
(2007)
Ann Intern Med
, vol.146
, pp. 829-838
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Enns, R.3
-
24
-
-
0030451949
-
Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease
-
Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996;39:684-689.
-
(1996)
Gut
, vol.39
, pp. 684-689
-
-
Reimund, J.M.1
Wittersheim, C.2
Dumont, S.3
-
25
-
-
0030981088
-
Tumour necrosis factor and Crohn's disease
-
Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997;40:443-448.
-
(1997)
Gut
, vol.40
, pp. 443-448
-
-
Van Deventer, S.J.1
-
26
-
-
0037358018
-
Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease
-
Agnholt J, Dahlerup JF, Buntzen S, et al. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment Pharmacol Ther. 2003;17:703-710.
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 703-710
-
-
Agnholt, J.1
Dahlerup, J.F.2
Buntzen, S.3
-
27
-
-
0033179725
-
Clinical relevance of serum interleukin-6 in Crohn's disease: Single point measurements, therapy monitoring, and prediction of clinical relapse
-
Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol. 1999;94:2156-2164.
-
(1999)
Am J Gastroenterol
, vol.94
, pp. 2156-2164
-
-
Reinisch, W.1
Gasche, C.2
Tillinger, W.3
-
28
-
-
0033835921
-
Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission
-
Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis. 2000;15:206-210.
-
(2000)
Int J Colorectal Dis
, vol.15
, pp. 206-210
-
-
Van Kemseke, C.1
Belaiche, J.2
Louis, E.3
-
29
-
-
0027451455
-
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
-
Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
-
(1993)
Clin Exp Immunol
, vol.94
, pp. 174-181
-
-
Reinecker, H.C.1
Steffen, M.2
Witthoeft, T.3
-
30
-
-
11144358366
-
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
-
Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-996.
-
(2004)
Gastroenterology
, vol.126
, pp. 989-996
-
-
Ito, H.1
Takazoe, M.2
Fukuda, Y.3
-
31
-
-
0028898529
-
Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation
-
Casini-Raggi V, Kam L, Chong YJ, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995;154: 2434-2440.
-
(1995)
J Immunol
, vol.154
, pp. 2434-2440
-
-
Casini-Raggi, V.1
Kam, L.2
Chong, Y.J.3
-
32
-
-
0036190776
-
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methitrexate: Results of twenty-four-week, multicenter, randomized,double-blind, placebo-controlled trial
-
Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methitrexate: results of twenty-four-week, multicenter, randomized,double-blind, placebo-controlled trial. Arthitis Rheum. 2002;43:614-624.
-
(2002)
Arthitis Rheum
, vol.43
, pp. 614-624
-
-
Cohen, S.1
Hurd, E.2
Cush, J.3
-
33
-
-
33646397611
-
IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6
-
Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310-1316.
-
(2006)
J Clin Invest
, vol.116
, pp. 1310-1316
-
-
Yen, D.1
Cheung, J.2
Scheerens, H.3
-
34
-
-
0035072493
-
VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: A novel mechanism of chronic intestinal inflammation
-
Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-828.
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 822-828
-
-
Kanazawa, S.1
Tsunoda, T.2
Onuma, E.3
-
35
-
-
27744485015
-
Posttranscriptional regulation of Smad7 in gut of patients with inflammatory bowel disease
-
Monteleone G, Del Vecchio Bianco G, Monteleone I, et al. Posttranscriptional regulation of Smad7 in gut of patients with inflammatory bowel disease. Gastroenterology. 2005;129:1420-1429.
-
(2005)
Gastroenterology
, vol.129
, pp. 1420-1429
-
-
Monteleone, G.1
Del Vecchio Bianco, G.2
Monteleone, I.3
-
37
-
-
1842586664
-
Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse
-
Yamamoto T, Umegae S, Kitagawa T, et al. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse. Aliment Pharmacol Ther. 2004;19:641-678.
-
(2004)
Aliment Pharmacol Ther
, vol.19
, pp. 641-678
-
-
Yamamoto, T.1
Umegae, S.2
Kitagawa, T.3
|